Naoko Nakanishi

Dr. Naoko Nakanishi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YNYuki Nakanishi
Yuki Nakanishi
HSHiroshi Seno
Hiroshi Seno
AFAyumi Fukuoka
Ayumi Fukuoka
TUTaro Ueo
Taro Ueo
YYYuichi Yamaga
Yuichi Yamaga
TCTsutomu Chiba
Tsutomu Chiba

25 June 2020 in Cancer Cell
Verified
Journal Article
Closed access
YKYotaro Kudo
Yotaro Kudo
MSMasayuki Sugimoto
Masayuki Sugimoto
EAEsperanza Arias
Esperanza Arias
HKHiroaki Kasashima
Hiroaki Kasashima
TCThekla Cordes
Thekla Cordes
JMJorge Moscat
Jorge Moscat

1 January 2012 in Atherosclerosis
Verified
Journal Article
Closed access
Hiroshi OkadaHiroshi Okada
Hiroshi Okada
Michiaki FukuiMichiaki Fukui
Michiaki Fukui
MTMuhei Tanaka
Muhei Tanaka
SIShinobu Inada
Shinobu Inada
YMYusuke Mineoka
Yusuke Mineoka
NNNaoto Nakamura
Naoto Nakamura

7 September 2011 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
NNNaoko Nakanishi
Naoko Nakanishi
Michiaki FukuiMichiaki Fukui
Michiaki Fukui
MTMuhei Tanaka
Muhei Tanaka
HTHitoshi Toda
Hitoshi Toda
SISaeko Imai
Saeko Imai
NNNaoto Nakamura
Naoto Nakamura
Background/Aims: A variety of risk factors for chronic kidney disease (CKD), including the metabolic syndrome, were recently reported. It has been suggested that a low urine pH is another characteristic of the metabolic syndrome. However, the relationship between urine pH and CKD remains to be elucidated. Methods: A cohort study was performed on 1,811 subjects who underwent a health check-up, and we examined whether low urine pH could be a predictor of CKD. The following risk factors for CKD were evaluated: age, gender, history of alcohol intake and smoking, BMI, systolic blood pressure, fasting plasma glucose, total cholesterol, uric acid, total leukocyte count, CKD stage, fasting urine pH, and protein at baseline. Results: We followed 1,811 subjects for a median period of 7.7 years. Three hundred and thirty-nine subjects developed stage 3 CKD defined as progression to estimated glomerular filtration rate <60 ml/min/1.73 m2. Multiple Cox regression analysis revealed that the adjusted HR (95% CI) for stage 3 CKD was 1.32 (1.06–1.65; p = 0.0129) in subjects with fasting urine pH 5.0–5.5 compared to subjects with pH 6.5–7.0. Conclusion: Our study suggests that low urine pH is an independent predictor of stage 3 CKD.

12 June 2013 in Diabetes Care
Verified
Journal Article
Open access
PDF file
Hiroshi OkadaHiroshi Okada
Hiroshi Okada
Michiaki FukuiMichiaki Fukui
Michiaki Fukui
MTMuhei Tanaka
Muhei Tanaka
SMShinobu Matsumoto
Shinobu Matsumoto
YMYusuke Mineoka
Yusuke Mineoka
NNNaoto Nakamura
Naoto Nakamura
OBJECTIVE Recent study has suggested that not only the presence of hypertension but also the variability in systolic blood pressure (SBP) are risk factors for vascular disease and organ damage. The aim of this study was to investigate the relationship between visit-to-visit variability in SBP and change in urinary albumin excretion (UAE) or development of albuminuria in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS We measured SBP in 354 consecutive patients at every visit during 1 year and calculated the coefficient of variation (CV) of SBP. We performed a follow-up study to assess change in UAE or development of albuminuria, the mean interval of which was 3.76 ± 0.71 years. Then, we evaluated relationships of variability of SBP to diabetic nephropathy using multiple regression analysis and multiple Cox regression model. RESULTS Multiple regression analysis demonstrated that CV of SBP was independently associated with change in UAE (β = 0.1758; P = 0.0108). Adjusted Cox regression analyses demonstrated that CV of SBP was associated with an increased hazard of development of albuminuria; hazard ratio was 1.143 (95% CI 1.008–1.302). CONCLUSIONS Visit-to-visit variability in SBP could be a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes.

1 September 2016 in Cell Reports
Verified
Journal Article
Open access
YNYuki Nakanishi
Yuki Nakanishi
MRMiguel Reina-Campos
Miguel Reina-Campos
NNNaoko Nakanishi
Naoko Nakanishi
VLVictoria Llado
Victoria Llado
LELisa Elmen
Lisa Elmen
JMJorge Moscat
Jorge Moscat
Paneth cells are a highly specialized population of intestinal epithelial cells located in the crypt adjacent to Lgr5(+) stem cells, from which they differentiate through a process that requires downregulation of the Notch pathway. Their ability to store and release antimicrobial peptides protects the host from intestinal pathogens and controls intestinal inflammation. Here, we show that PKCλ/ι is required for Paneth cell differentiation at the level of Atoh1 and Gfi1, through the control of EZH2 stability by direct phosphorylation. The selective inactivation of PKCλ/ι in epithelial cells results in the loss of mature Paneth cells, increased apoptosis and inflammation, and enhanced tumorigenesis. Importantly, PKCλ/ι expression in human Paneth cells decreases with progression of Crohn's disease. Kaplan-Meier survival analysis of colorectal cancer (CRC) patients revealed that low PRKCI levels correlated with significantly worse patient survival rates. Therefore, PKCλ/ι is a negative regulator of intestinal inflammation and cancer through its role in Paneth cell homeostasis.